Who
Hans-Peter Gerber
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Sutro Biopharma.
In numbers
- Trades disclosed
- 39
- Buys
- 1
- Sells
- 0
- Bought
- $14K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 18 Sep 2023
- Last trade
- 18 Sep 2026
- Last filed
- 22 Sep 2026
Companies traded
Activity over time
1 Oct 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Sep 2026filed 22 Sep 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 18 Sep 2026filed 22 Sep 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code F | $21K1,345 at $15.34 | filing |
| 18 Sep 2026filed 22 Sep 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 18 Sep 2026filed 22 Sep 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 18 Sep 2026filed 22 Sep 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 18 Sep 2026filed 22 Sep 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code F | $21K1,345 at $15.34 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —2,843 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,843 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code F | $24K1,170 at $20.55 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,843 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —2,843 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code F | $24K1,170 at $20.55 | filing |
| 1 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —1,125 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code F | $9,478463 at $20.47 | filing |
| 1 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,125 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,125 at $0.00 | filing |
News
Tenaya Therapeutics (NASDAQ:TNYA) versus Sutro Biopharma (NASDAQ:STRO) Head-To-Head ComparisonSTRO · themarketsdaily.com · 20 Oct 2026
0 headlines in the last 90 days name Hans-Peter Gerber; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.